<DOC>
	<DOCNO>NCT03088709</DOCNO>
	<brief_summary>Historically , best result allogeneic SCT obtain stem cell donor human leukocyte antigen ( HLA ) -matched sibling , however , available approximately 30 percent patient need SCT . Alternative donor source include match unrelated donor utilize donor registry , cord blood transplant mismatch donor transplant . A human leukocyte antigen ( HLA ) -haploidentical donor one share , common inheritance , exactly one HLA haplotype recipient , include biologic parent , biologic child full half sibling . There strong body evidence support use haplo-SCT patient lack match sibling unrelated donor high rate successful engraftment , effective Graft Versus Host Disease ( GVHD ) control favorable outcome comparative see use allograft source , include HLA-matched sibling SCT . Furthermore , provide cost-efficient donor option timely manner especially patient need proceed quickly transplant due concern disease relapse/progression .</brief_summary>
	<brief_title>Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide</brief_title>
	<detailed_description>An open label , single-arm , single-center study evaluate safety , efficacy feasibility haplo-SCT alternative donor source patient lack match sibling/unrelated donor option . The choice chemotherapy treatment transplantation investigator . Post-transplant cyclophosphamide serve backbone immunosuppression treatment prevent GVHD . GVHD Prevention Treatment : Cyclophosphamide administer IV Day 3 Day 7 post transplant . Tacrolimus administer IV patient take mouth start day transplant continue approximately 100 day post-transplant . Mycophenolate mofetil administer IV patient take mouth start Day 1 post transplant 28 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Ages 16 year old Performance Status 70 percent Patients follow disease : Acute myelogenous leukemia ( AML ) Acute lymphocytic leukemia lymphoblastic lymphoma ( ALL ) Transfusion dependent myelodysplastic syndrome ( MDS ) NonHodgkin 's Lymphoma ( NHL ) Chronic lymphocytic leukemia ( CLL ) Pulmonary function measure forced expiratory volume one second ( FEV1 ) and/or correct diffuse capacity lung carbon monoxide ( DLCO ) 60 percent predict Left ventricular ejection fraction 45 percent If donorspecific HLA antibody ( DSA ) positive , patient must undergo desensitization protocol result undetectable DSA prior day transplant Less twentyone day elapse since subject 's last radiation chemotherapy prior conditioning ( except hydroxyurea ) Uncontrolled bacterial , fungal viral infection time study enrollment Positive HIV , human Tcell leukemia virus ( HTLV1 ) and/or Hepatitis C Subjects signs/symptoms active central nervous system ( CNS ) disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>GVHD</keyword>
</DOC>